Lili Duda, VMD
Ultima Vez Modificado: 1 de noviembre del 2001
Dear OncoLink "Ask the Experts,"
Our dog has been diagnosed with myxofibrosarcoma. Given the tumor's size, location and aggressiveness, and the consequent difficulty of securing a tumor-free margin without extensive penetration into the chest, we are considering palliative care options. This is where the questions arise:
Lili Duda, VMD, Editor of the OncoLink Veterinary Oncology Section, responds:
Superficial ulceration of large tumors is a frequent complication. It is unlikely that fluid-filled pockets within a tumor are much of a contributing cause of surface ulceration, and aspiration is not likely to be very helpful. However, in the few cases where a tumor does contain a solitary, large fluid-filled center, aspiration might be helpful to relieve the pressure. Ultrasound is recommended to confirm the presence of a fluid-filled area prior to aspiration. The procedure should be performed using sterile conditions in order to minimize the risk of infection. Another palliative treatment option that might provide temporary relief is radiation therapy. Chemotherapy might also provide short-term palliation in some cases.
For locally invasive tumors that either do not metastasize or metastasize late in the progression of the cancer, tumor associated problems are generally localized problems. The presence of necrosis, ulceration and bleeding are part of the cancer "running its course", and it is these types of complications that often result in a decision for euthanasia. Systemic problems are unlikely to occur unless the localized infection and inflammation at the tumor site become so severe that the problems become systemic. Even if metastasis does occur, it is often asymptomaticit is the primary tumor that causes the majority of the symptoms in most cases.
For most purposes, low-grade soft tissue sarcomas have a similar clinical course. Some tumors do tend to be firmer and more solid, and some tend to be softer and more fluid. In addition, many tumors, and in particular rapidly growing tumors may have a central area of dead, liquefied tumor cells. However, the particular type of sarcoma (fibrosarcoma vs. myxosarcoma for example) does not make a difference in case management or outcome.
Dec 7, 2010 - Rituximab may be a better option than watchful waiting in some lymphoma patients, and a new treatment option appears effective for relapsed or refractory Hodgkin's lymphoma, according to two studies being presented at the annual meeting of the American Society of Hematology, held from Dec. 4 to 7 in Orlando, Fla. Other research being presented will highlight new options for the standard treatment of advanced asymptomatic follicular lymphoma; mantle cell lymphoma; and early, unfavorable Hodgkin's disease.